PLEASANTON, Calif.--(BUSINESS WIRE)--May 18, 2018--
NeoTract, a wholly owned subsidiary of Teleflex Incorporated
(NYSE: TFX) focused on addressing unmet needs in the field of urology,
today announced that the American Urological Association (AUA) has
recommended the use of theUroLift® System as a
standard of care treatment for lower urinary tract symptoms due to
benign prostatic hyperplasia (BPH).
In its newly released clinical
guidelines developed by a panel of experts in the field, the AUA
recommends that the UroLift Prostatic Urethral Lift procedure should be
considered for the management of men’s lower urinary tract symptoms
attributed to BPH. The guidelines, last revised in 2010, were
distributed to peer reviewers prior to approval by the AUA Board of
Directors.
The AUA notes that, given the strong observed relationship between
erectile dysfunction and BPH, this group of men is at high risk for
sexual dysfunction. The organization recommends that patients should be
counselled about the sexual side effects of any surgical intervention
and should be made aware that surgical treatment can cause ejaculatory
dysfunction and may worsen erectile dysfunction. The UroLift System is
the only minimally invasive treatment option that has been shown to
provide rapid and durable symptomatic and urinary flow rate improvement
without inducing sustained sexual dysfunction.
“The AUA is strongly committed to doing what is best for patients. With
the inclusion of the UroLift System in these new guidelines, the AUA
provides support of the UroLift System as a treatment in the best
interest of patients,” said Dave Amerson, president of the NeoTract
Interventional Urology business unit. “Following treatment with the
UroLift System, thousands of men have avoided invasive surgery, are no
longer needing medications, and are back to living their lives, without
giving up normal sexual function. We are hopeful that this
recommendation from AUA will mean that many more men will choose the
UroLift System.”
BPH is marked by bothersome urinary symptoms that can cause loss of
productivity, depression, interrupted sleep, and decreased quality of
life. It is not a pre-cursor to prostate cancer, but is twelve times
more common, especially as men age. Over 40 percent of men in their 50s
have BPH and over 70 percent of men in their 60s have the condition. The
incidence rate climbs to 80 percent for men over the age of 70. If BPH
is left untreated, the condition can worsen over time and cause
permanent bladder damage.
UroLift System Results to be Featured in Late-Breaker at AUA
Annual Meeting
Additionally, the company announced activities planned for the 113thAmerican Urological Association Annual Meeting, taking place May 18-21
at the Moscone Convention Center in San Francisco. These presentations
include:
Friday, May 18
-
Video session presentation by Dr. Thomas Mueller: Performance of
Prostatic Urethral Lift in Men with Prostate Volumes <30 grams and >80
grams (7:30 – 9:30 a.m., MCC WEST, 3002)
Saturday, May 19
-
UroLift technique video presentation by Dr. Gregg Eure: Surgical
Techniques: Tips & Tricks: Benign Prostatic Hyperplasia (3:00
– 4:00 p.m., MCC South, Esplanade)
Sunday, May 20
-
Late-breaking abstract presentation by Dr. Daniel Rukstalis: Multi-Center
Prospective Study of the Prostatic Urethral Lift for Obstructive
Median Lobe: The MedLift Study, An Extension of the LIFT Randomized
Study (4:05 – 4:15 p.m. in MCC North, Hall E)
-
Moderated poster presentation by Dr. Steven Kaplan: Predictors of
Response to the Prostatic Urethral Lift Treatment (1:00 – 3:00
p.m. in MCC West, 3006)
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. Patients also experienced a significant improvement in
quality of life. More than 50,000 men worldwide have been treated with
the UroLift System. Most common adverse events reported include
hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The UroLift
System is available in the U.S., Europe, Australia, Canada, Mexico and
South Korea. Learn more at www.UroLift.com
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract
Interventional Urology Business Unit is dedicated to developing
innovative, minimally invasive and clinically effective devices that
address unmet needs in the field of urology. Our initial focus is
on improving the standard of care for patients with BPH using the
UroLift System, a minimally invasive permanent implant system that
treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®
and Weck® – trusted brands united by a common sense of
purpose.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180518005114/en/
Source: Teleflex Incorporated
For Teleflex Incorporated
Jake Elguicze, 610-948-2836
Treasurer
and Vice President, Investor Relations
or
Media:
Nicole
Osmer, 650-454-0505
nicole@healthandcommerce.com